Dibutyryl-cAMP (Na Salt), 25 mg

A cell-permeable cyclic AMP analog supplied by STEMCELL Technologies as a crystalline solid, this cAMP pathway activator is provided as the monosodium salt (CAS 16980-89-5) and is also known as bucladesine, referenced in the documentation as DC 2797. The chemical name is N-(1-oxobutyl)-cyclic 3',5'-(hydrogenphosphate) 2'-butanoate-adenosine, monosodium salt, with a molecular weight of 491.4 g/mol, a chemical formula of C₁₈H₂₃N₅O₈P · Na, and a reported purity of ≥ 95%. The compound activates cAMP-dependent protein kinases.

The supplier documents published differentiation-related applications: the compound has been reported to suppress experimental autoimmune encephalomyelitis development by reducing demyelination (Khezri et al., 2013), to induce intrinsic axon growth in peripheral and central nervous systems and morphological differentiation of astrocytes (Knott et al., 2014; Imamura & Ozawa, 1998), and to stimulate neurite outgrowth in PC12 cells (Maruoka et al., 2010). The product is documented as stable at -20 °C as supplied, with protection from prolonged light exposure and storage with a desiccant recommended; it is stated to remain stable as supplied for 12 months from the date of receipt. Stock preparation guidance indicates water and DMSO concentrations of ≤ 100 mM, with advice to avoid final DMSO concentrations above 0.1% in cell culture due to potential toxicity.

Safety documentation describes the substance as not classified as hazardous according to the Globally Harmonized System (GHS), while noting it may be harmful in contact with skin. Reported solubility values are approximately 3.3 mg/mL in PBS (pH 7.2), approximately 1 mg/mL in ethanol, and approximately 5 mg/mL in DMF. Reported acute toxicity values in rats are an oral LD50 greater than 5 g/kg and a dermal LD50 greater than 2 g/kg.